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Abstract. Although the past few decades have shown an improvement in the survival and 
complication-free survival rates in patients with beta-thalassemia major and gene therapy is 
already at an advanced stage of experimentation, hematopoietic stem cell transplantation 
(HSCT) continues to be the only effective and realistic approach to the cure of this chronic non-
malignant disease. Historically, human leukocyte antigen (HLA)-matched siblings have been the 
preferred source of donor cells owing to superior outcomes compared with HSCT from other 
sources. Nowadays, the availability of an international network of voluntary stem cell donor 
registries and cord blood banks has significantly increased the odds of finding a suitable HLA 
matched donor. Stringent immunogenetic criteria for donor selection have made it possible to 
achieve overall survival (OS) and thalassemia-free survival (TFS) rates comparable to those of 
sibling transplants. However, acute and chronic graft-versus-host disease (GVHD) remains the 
most important complication in unrelated HSCT in thalassemia, leading to significant rates of 
morbidity and mortality for a chronic non-malignant disease. A careful immunogenetic 
assessment of donors and recipients makes it possible to individualize appropriate strategies for 
its prevention and management. This review provides an overview of recent insights about 
immunogenetic factors involved in GVHD, which seem to have a potential role in the outcome of 
transplantation for thalassemia. 
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Unrelated Hematopoietic Stem Cell 
Transplantation for Thalassemia. Beta 
thalassemia major is an inherited 
hemoglobinopathy characterized by anemia and 
chronic hemolysis,
1
 affecting several dimensions 
of the patient’s life such as education, free-time, 
physical activities, skills, family life and often 
results in anxiety, depression and lower health 
related quality of life (HRQoL).
2,3
 Blood 
transfusions and chelation practice have been 
routinely performed in the management of these 
patients.
2,4,5
 
 Until now, despite the promising outcomes 
coming from clinical trials on gene therapy, 
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hematopoietic stem cell transplantation (HSCT) 
remains the only curative approach for this severe 
genetic disorder. Since its first successful 
application in 1981, more than 3,000 thalassemia 
patients have been transplanted worldwide. The 5-
year probabilities of overall survival (OS) and 
thalassemia free survival (TFS) are currently 
estimated to be between 87% to 97% and 80% to 
89% respectively.
6
 Despite successful HSCT 
eliminates the need for blood transfusions, pre-
transplant clinical conditions, as well as clinical 
complications and adverse effects of therapy,  
contribute to the impairment of HRQoL.
7
 
Nevertheless, a study in a large cohort of ex-
thalassemia patients who underwent HSCT more 
than 20 years ago showed that the ex-patients, 
their sibling donors, and the general population 
had a very similar HRQoL and that the latter was 
even better in the ex-patients than a control group 
of thalassemic patients treated conventionally with 
blood transfusions and iron chelation therapy.
8
 
Human leukocyte antigen (HLA) compatible 
marrow stem cells from identical sibling donor 
represent the goal choice for thalassemia patients 
requiring allogeneic HSCT. However, the 
probability of finding a compatible donor within 
the family ranges from 25% to 30%. For the 
remaining patients, HSCT from an unrelated 
voluntary donor is a feasible alternative. In recent 
years, the growing availability of alternative stem 
cell sources (marrow from an unrelated or 
haploidentical donor and hematopoietic stem cells 
from umbilical cord blood) has made HSCT a 
feasible option for an increasing number of 
patients in search of a compatible donor. By 
applying highly stringent criteria for donor 
selection, the outcome of unrelated HSCT is not 
much different from that obtained when using a 
compatible sibling with a 5-year probability of OS 
and TFS of 84% and 75%, respectively.
9
 So far, 
more than 300 thalassemia patients have been 
transplanted from an unrelated donor. Table 1 
illustrates the outcome of unrelated HSCT and 
cord blood transplantation (CBT) performed to 
cure children and young adults with beta 
thalassemia major, using both myelo-ablative and, 
more recently, reduced-intensity conditioning 
regimens. 
 
Graft Versus Host Disease in Unrelated HSCT. 
Unfortunately, acute and chronic Graft Versus 
Host Disease (GvHD), a potentially multi-
systemic disorder caused by immunoeffector 
donor lymphocytes that destroy host tissues, 
remains the main treatment-related cause of death 
in unrelated HSCT in thalassemia.
10
 The 
prevention of acute or chronic GvHD in 
thalassemia patients undergoing unrelated HSCT 
represents a critical issue. GvHD is actually a 
complication without any benefits (Graft-versus-
Leukemia effect) for patients with a chronic non-
malignant disease. Therefore, the minimization of 
 
Table 1. Clinical outcomes of unrelated hematopoietic stem cell transplantation and cord blood transplantation in young adult and pediatric 
thalassemia patients. 
First 
author 
N° pts Source 
Age 
median years 
(range) 
OS 
(%) 
TFS 
(%) 
TRM 
(%) 
Rejection 
(%) 
aGvHD 
(%) 
cGvHD 
(%) 
La Nasa 
(2002)12 
32 BM 14 (2-28) 79 66 19 12.5 41 25 
La Nasa 
(2005)13 
68 BM 15 (2-37) 79.3 65.8 20 13 40 18 
Hongeng 
(2006)51 
21 BM 4 (0.7-12) 85.7 71 14.3 14.3 42 14 
Locatelli   
(2011)9 
122 BM 10.5 (1-35) 84 75 16.4 13.1 28 13 
Ruggeri   
(2011)17 
35 CB 4 (0.5-14) 62 21 34 57 23 16 
Jaing 
(2012)16 
35 CB 5.5 (1.2-14) 88.5 88.5 11.4 0 47 35 
Li 
(2012)15 
52 BM/PB 6 (2-15) 92.3 90.4 7.7 1.9 9.6 0 
Anurathapan 
(2014)52 
26 BM/PB 8 (2-10)  94 82 7 0 28 15 
Shah 
(2015)18 
9 CB 3.8 (1.5-7) 100 56% 0 44% 33% 11% 
BM: bone marrow; CB: cord blood; PB: peripheral blood; OS: overall Survival; TFS: Thalassemia Free Survival; TRM: Transplantation-
related mortality; aGvHD: acute graft versus host disease; cGvHD: chronic graft versus host disease. 
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GvHD immunogenetic risk is mandatory. Indeed, 
GvHD is not only associated with a high mortality 
risk, but it can also seriously impair the post-
transplant HRQoL. Although immunosuppressive 
therapy represents the fundamental approach to the 
prevention of this severe complication, careful 
donor selection can result in marked improvement 
in the outcomes. The incidence of GvHD is highly 
variable from individual to individual due to 
several modifiable and non-modifiable risk 
factors, such us the conditioning regimen intensity, 
the stem cell source, the degree of human 
leukocyte antigen (HLA) mismatch, the previous 
alloimmunization in the donor, the use of total 
body irradiation, the GvHD prophylaxis, the 
severity of individual organ insufficiencies, the 
female vs male donor recipient, the recipient age 
and the transplantation risk class according to the 
Pesaro classification (hepatomegaly, liver fibrosis 
and inadequate chelation therapy).
11
 
Historically, the first series of 32 transplants 
from bone marrow HSC of unrelated donor 
(median age 14 years, range 2-28 years) was 
published in 2002.
12
 Severe acute GvHD was 
registered in 41% of cases and chronic GvHD in 
25%. In 2005, the same research group extended 
the study to 68 thalassemia patients.
13
 In this 
cohort, 25% of patients received anti-thymocyte 
globulin (ATG, 3.5 mg/kg) for GvHD prophylaxis, 
in addition to cyclosporine (CSP) and short 
courses of methotrexate (MTX). Nevertheless, 
40% of the patients developed severe acute GVHD 
and 18% chronic GVHD. In the following years, 
the Italian cohort of thalassemia patients 
transplanted from unrelated donors rose to over 
100 cases; in 2011, a report at the annual ASH 
meeting, presented outcomes of 122 thalassemia 
patients (median age 10,5 range 1-35 years).
9
 
Interestingly, the myeloablative conditioning 
regimen in 40 patients was slightly different, since 
it was based on the combination of conventional 
drugs with treosulfan (Treo).
14
 All patients 
received homogeneous GvHD prophylaxis 
consisting of CSP, short courses MTX and ATG, 
and donor selection was based on high resolution 
HLA typing. Acute and chronic GvHD dropped to 
28% and 13%, respectively. This treosulfan-based 
preparation proved to be safe and effective for 
thalassemia patients undergoing allogeneic HSCT.  
With regard to alternative stem cell sources, an 
experience with granulocyte colony-stimulating 
factor (G-CSF)-mobilized peripheral HSC was 
described in 2012.
15
 GvHD prophylaxis consisted 
of CSP, mycophenolate mofetil (MMF), short 
courses MTX and ATG. The mean dose of CD34+ 
cells that were infused was 6.81x10
6
/kg. These 
authors reported a very low percentage of acute 
GvHD (9.6%) and no cases of chronic GvHD. 
These findings are even more surprising if we 
consider that the peripheral source of HSC is 
usually related to a higher rate of GvHD if 
compared to bone marrow HSC. Current research 
is focused on the use of cord blood (CB) as an 
alternative HSC source in unrelated 
transplantation for thalassemia. In a pediatric 
setting, this option has the advantage of being 
immediately available when required and CB is 
not as difficult to match as stem cells from an 
adult volunteer donor. Incidence of GvHD is 
widely variable both for acute (23-47%) and 
chronic form (11-35%).
16,17,18
 Unfortunately, 
rejection rates remain very high (Table 1).
17,18
 
Overall, GvHD causes severe morbidity, and 
long survivors have a severely compromised 
HRQoL. Recently, there has been a growing 
interest in immunogenetic variables that seem to 
have a potential role in the outcome of 
transplantation for thalassemia, capable of 
predicting the onset of GvHD  
 
Role of HLA-DPB1. Over the past years, the 
concept of “permissive” or “non-permissive” 
HLA-DPB1 disparities and their influence on 
transplantation outcome, with specific reference to 
acute GvHD and rejection, has aroused 
considerable interest. HLA-DP antigens are 
involved in both humoral and cellular alloresponse 
and are encoded by genes at the DPA1 locus, 
which displays limited polymorphism, at the 
highly polymorphic DPB1 locus.
19
 Because of the 
weak linkage disequilibrium existing between the 
DR/DQ and DP loci, only 20% of matched 
unrelated donor-recipient pairs are also compatible 
for HLA-DPB1, while about 80% are transplanted 
across the HLA-DPB1 barrier. A previous study 
has proposed an algorithm based on in vitro 
donor/recipient immune-reactivity, which was 
found to be associated with a significantly 
increased risk of transplantation-related mortality 
(TRM) and severe acute GVhD in patients 
undergoing transplantation for malignant 
hematopoietic disorders
 
(Figure 1).
20
 The 
algorithm divided HLA-DPB1 alleles into 3 
groups according to in vitro immunogenicity
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Figure 1. Risk assessment of acute graft-versus-host disease and rejection according to permissive and nonpermissive HLA-DPB1 
mismatches in donor and recipient pairs. 
 
testing and classified the risk of rejection or GvHD 
for each of the 6 different combinations present in 
diploid cells. On the basis of cross-reactive 
patterns by alloreactive T cells involved in HSCT 
rejection targeted to HLADPB1*0901, the 
algorithm divides HLA-DPB1 alleles into 3 groups 
with high (HLA-DPB1*0901,*1001,*1701), 
intermediate (HLA-DPB1 *0301,*1401,*4501), or 
low (most other HLADPB1 alleles) 
immunogenicity, on the basis of a shared 
alloreactive T-cell epitope.
20
 
A study on 72 thalassemia patients receiving 
unrelated HSCT confirmed that the risk of 
rejection was associated with the presence of non-
permissive HLA-DPB1 mismatches in the host-
versus-graft (HvG) direction, as predicted by the 
algorithm.
21
 TFS was reduced in patients with 
non-permissive HLA-DPB1 mismatches in HvG 
(59%) or GvHD (60%) direction, as compared to 
the matched or permissive group (78%). The 
authors suggested that implementation of standard 
criteria for donor selection may highlight the 
crucial role of immunogenetic factors in the 
occurrence of complications due to alloreactivity 
following unrelated donor HSCT for beta-
thalassemia. The clinical predictive value of the 
aforesaid algorithm was retrospectively confirmed 
in a study of 621 unrelated HSCT from the Italian 
Bone Marrow Donor Registry and in a large 
cohort of 8,539 transplanted patients.
22,23
 Non-
permissive mismatches were associated with a 
significantly increased risk of TRM and severe 
acute GvHD, compared to permissive mismatches. 
These results suggest that HSCT from unrelated 
donors with a non-permissive T-cell-epitope 
mismatch at HLA-DPB1 deserves careful 
consideration, particularly in the setting of a 
chronic non malignant disease like thalassemia, 
where it is important to lower the risks of GvHD 
and TRM. The DPB1 algorithm for donor 
selection is a powerful tool for the prediction of 
complications in thalassemia patients undergoing 
unrelated HSCT.  
 
Role of HLA-G. Another molecule that could play 
a role in immune modulation after HSCT is human 
leukocyte antigen G (HLA-G). HLA-G is a non-
classical MHC class I molecule of low 
polymorphism and restricted tissue distribution. It 
is highly expressed in trophoblast cells and plays a 
critical role in embryo implantation and pregnancy 
by contributing to maternal immune tolerance of 
the fetus through its immunosuppressive effects on 
all types of immune cells.
24
 The HLA-G gene is 
located on the short arm of chromosome 6, in the 
HLA region 6p21.2-21.3, between the HLA-A and 
HLA-F genes.
25
 The HLA-G primary transcript 
generates 7 alternative messenger ribonucleic 
acids (mRNAs) that encode 3 different soluble 
isoforms sHLA-G1 or HLA-G5, HLA-G6, and 
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HLA-G7 and 4 isoforms with transmembrane and 
cytoplasmic domains HLA-G1, -G2, -G3, -G4.
26
 
HLA-G allelic variants may also be characterized 
by a 14-basepair (bp) deletion-insertion 
polymorphism located in the 3’-untranslated 
region of the HLA-G gene.  The presence of the 
14-bp insertion is known to generate additional 
mRNA splicing.
26,27
 It would seem that spliced 
mRNAs are more stable than their corresponding 
cDNA transcript counterparts, and thus determine 
an increment in HLA-G expression. The influence 
of the 14-bp deletion/insertion polymorphism on 
the outcome of HSCT was retrospectively 
investigated in 53 patients affected by thalassemia 
major transplanted from an unrelated donor.
28
 The 
risk of developing acute GvHD was higher in 
patients homozygous for the 14-bp deletion 
compared to patients carrying the 14-bp insertion. 
The authors suggested that this finding could be 
related to the increased production of HLA-G 
molecules and proposed the evaluation of the 
HLA-G 14-bp insertion-deletion polymorphism in 
the pre-transplantation risk-assessment process. 
 
Role of CTLA-4. The co-receptor cytotoxic T-
lymphocyte antigen-4 (CTLA-4) is a molecule 
involved in regulating the duration and severity of 
immune response after HSCT. CTLA-4, also 
known as CD152, is one of the most important 
members of the immunoglobulin superfamily and 
it is a vital restraining regulator of T-cell 
proliferation and activation, inducing Fas-
independent apoptosis of activated T cells.
29,30
 
CTLA-4 is akin to CD28 molecule both of them 
bind B7.1 and B7.2 on antigen-presenting cells 
(APC), with a much higher affinity of CTLA-4 
than CD28. The mechanisms through which 
CTLA-4 plays a role as a negative regulator are 
multiple, including the reduction of both 
interleukin (IL)-2 and IL-2 receptor production 
and the T cells block at the G1 phase in the cell 
cycle.
31,32
 The CTLA4 gene is located on human 
chromosome 2q33 and consists of four exons: the 
exon 1 contains the leader peptide sequence, the 
exon 2 the ligand binding site, the exon 3 encodes 
the transmembrane region, and the exon 4 the 
cytoplasmic tail. Differential splicing of the 
CTLA-4 transcript results in a full length 
transmembrane form (exons 1–4), soluble CTLA-4 
(lacking exon 3), and a transcript encoding only 
for exons 1 and 4;
33
 the alternative splicing that 
generates these isoforms seems to be regulated by 
genetic polymorphisms.
34
 Polymorphisms of the 
CTLA-4 gene have been associated with 
autoimmune diseases and, more recently, with the 
outcome of allogeneic HSCT in leukemia 
patients.
35
 A previous study reported the role of 
CTLA-4 gene polymorphisms in the onset of acute 
GvHD following unrelated HSCT in a cohort of 
thalassemia patients transplanted at a mean age of 
13 years.
36
 The genotype distribution for each 
CTLA-4 polymorphism was compared according 
to the presence or absence of acute GvHD.  
Patients homozygous for the CT60-A allele had a 
significantly higher probability of developing 
acute GvHD than patients with the CT60-G allele. 
According to the authors, the protective effect of 
the G-allele may be due to down-regulation of 
soluble CTLA-4 expression levels. On the other 
hand, the higher levels of soluble CTLA-4 
associated with CT60-A homozygosity may 
hamper binding of B7 with membrane-bound 
CTLA-4 expressed on activated T cells and thus 
increase their reactivity. These data indicate that 
the genetic risk factors for GVHD may also 
depend on the recipient genotype and that the 
portion of residual T-cells may play a major role 
in the outcome of HSCT for thalassemia.  
 
Role of Killer Cell Immunoglobulin-like 
Receptors (KIRs). HLA class I molecules and 
killer cell immunoglobulin-like receptors (KIRs) 
are of pivotal importance for regulating natural 
killer (NK) cell function. Previous studies have 
shown that donor NK cell alloreactivity exerts a 
graft-versus-leukemia effect which reduces the 
risk of GvHD  through lysis of recipient antigen-
presenting cells (APCs).
37
 
In humans, two different types of HLA class-I-
specific inhibitory receptors exist: KIRs, also 
referred to as CD158, that in most instances, 
recognize the polymorphic HLA-A, -B, and -C 
molecules, and CD94/NKG2A (CD94/CD159a), a 
heterodimer related to C-type lectins that 
recognize HLA-E, a non-classical MHC molecule 
characterized by a limited polymorphism. KIRs 
are transmembrane glycoproteins containing two 
(D1 and D2, designated KIR2D) or three (D0, D1, 
and D2, designated KIR3D) extracellular C2-type 
Ig-like domains, while KIR2D receptors bind 
HLA-C alleles, KIR3D receptors bind HLA-A and 
HLA-B alleles.
38,39
 Depending on to the function 
performed, the intracytoplasmatic domains of 
KIRs can feature either a short (called activating 
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KIRs) or a long (called inhibitory KIRs) 
cytoplasmic tail, “S” or “L” in the nomenclature, 
respectively.
40
 In particular, reduced activity of 
NK cells may be related to the balancement 
between inhibitory (KIR2DL1, KIR2DL2, 
KIR2DL3, KIR2DL4, KIR2DL5, KIR3DL1, 
KIR3DL2, KIR3DL3) and activating (KIR2DS1, 
KIR2DS2, KIR2DS3, KIR3DS1) KIR genes.
41
 All 
people may differ strongly in the activating KIR 
content. In particular, two different types of KIR 
haplotypes can be distinguished in humans: A and 
B.  In general, haplotypes A are beneficial in NK 
responses to pathogens, whereas haplotypes B are 
associated with low frequencies of pregnancy 
disorders.
42
 KIR haplotype A contains six 
inhibitory KIR genes and a single activating KIR 
gene (KIR2DS4), while KIR haplotype B contains 
various combinations of both activating and 
inhibitory KIR genes.
43,44
 Moreover, KIR 
hapotype A may completely lack expression of 
activating KIRs on the NK cell surface depending 
on functional or non-functional variants of the 
only activating receptor KIR2DS4.
45
 These 
receptors prevent NK cell-mediated attack against 
normal autologous cells and allow the killing of 
cells that upon tumor transformation or viral 
infection present compromised HLA class-I 
expression (“missing self hypothesis”).46 
Until now, few studies have reported the 
influence of KIRs on HSCT. A study investigating 
the impact of KIRs and their ligands on the 
outcome of unrelated HSCT was conducted in a 
cohort of transfusion-dependent beta-thalassemia 
patients.
47,48
 Donors and recipients were divided 
into two groups according to combinations of 
group A and group B KIR haplotypes: those 
homozygous for KIR haplotype A (AA) and those 
either heterozygous or homozygous for KIR 
haplotype B (AB+BB). The authors found that 
patients transplanted from AA homozygotes had a 
fourfold risk of developing moderate acute GvHD 
and a sevenfold risk of developing severe acute 
GvHD. Considering that the A haplotype only 
includes one stimulatory KIR (2DS4), which in 
most cases is not expressed on the NK cell 
membrane and thus remains ineffective, the 
authors postulated that NK cells in donors 
expressing only the A haplotype could display a 
lower efficiency in killing recipient APCs. By 
interpolating the number of donor activating KIRs 
with recipient HLA-C KIR ligands, the authors 
proposed an algorithm that is apparently capable 
of stratifying patients according to the 
immunogenetic risk of complications following 
transplantation (Figure 2).
49 
 
Figure 2. Algorithm showing the risk of developing acute GvHD or rejection after unrelated HSCT according to recipient KIR ligands and 
the number of donors activating KIRs. aGVHD= acute Graft Versus Host Disease. 
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Figure 3. The path from GvHD to immune tolerance is like a bridge where many variables are still missing. 
 
Based on the amino acid sequence at position 
80, HLA-C allotypes can be divided into two 
groups.  HLA-C1 has an asparagine at position 80 
whereas HLA-C2 has a lysine. According to 
reports in the literature, HLA-C1 binds the 
KIR2DL2 and KIR2DL3 inhibitory receptors and 
the KIR2DS2 and KIR2DS3 activating receptors, 
whereas HLA-C2 binds the KIR2DL1 inhibitory 
receptor and the KIR2DS1 activating receptor. 
Homozygosity or heterozygosity for C1 and C2 
KIR ligand groups and the number of donors 
activating KIR genes have been found associated 
with HSCT outcome. Donors homozygous for 
KIR haplotype A who only carry deletion variants 
of KIR2DS4 (the only activating KIR of the A 
haplotype) seem to be incapable of expressing 
functional activating KIRs on the NK cell surface. 
The purpose of the algorithm was to assess the risk 
of developing acute GvHD or rejection according 
to combinations of recipient HLA KIR ligand 
groups C1/C2, C1/C1 and C2/C2 and the number 
of donors activating KIRs (0, 1, ≥2). The highest 
risk of acute GvHD was observed for C1/C2 
heterozygotes transplanted from donors 
completely lacking functional activating KIRs. 
Conversely, the risk of acute GvHD was entirely 
absent in C2/C2 homozygotes transplanted from 
donors possessing ≥2 activating KIRs. Consistent 
with these findings, the authors proposed using the 
algorithm as a supportive tool in pre-HSCT risk 
assessment.
49
 
 
Conclusions. More in-depth comprehension of 
immunogenetic factors associated with a reduced 
risk of GvHD and TRM may possibly assist us in 
the selection of an ideal donor for a patient 
affected by thalassemia. Understanding the role of 
genetic factors capable of influencing the onset of 
GvHD is fundamental to the increasingly safer 
application of unrelated HSCT in thalassemia, 
particularly if we consider that GvHD is the 
leading cause of morbidity and mortality in this 
setting.
8
 Several variables seem to have a role in 
GvHD onset, but a clear vision of the whole 
problem is still missing (Figure 3).  
Careful assessment of all the immunogenetic 
variables discussed in this review is needed to 
optimize the accuracy of pre-transplantation risk 
assessment.  Data on HLA-G, CTLA-4 and KIR 
variables need further validations within 
prospective studies and multivariate analyses 
before a standard use in clinical practice could be 
suggested. Such an approach, with the support of 
mathematical software and statistics, should form 
a sound informative basis from which to derive 
strategies for the prevention of acute GvHD 
following HSCT for a chronic non-malignant 
disease.
50
 In conclusion, unrelated HSCT 
outcomes in thalassemia will continue to improve, 
with lower TRM and better OS and TFS rates. 
Prevention of GvHD through careful evaluation of 
immunogenetic features of donor and recipient 
pairs has a key role in this curative approach to 
beta thalassemia major. 
 
Key Issues: 
 Allogeneic hematopoietic stem cell 
transplantation (HSCT) is currently the only 
treatment capable of definitively correcting the 
defective erythropoiesis in beta thalassemia 
major. 
 The probability of finding a compatible donor 
within the family ranges from 25 to 30%. For 
other patients, HSCT from an unrelated 
voluntary donor is a feasible alternative. 
 By applying highly stringent criteria for donor 
selection, the outcome of unrelated HSCT is not 
much different from that obtained when using a 
compatible sibling  
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 Graft versus host disease (GvHD) remains a 
significant treatment-related cause of death in 
unrelated HSCT for thalassemia  
 Human leukocyte antigen-DPB1 (HLA-DPB1) 
disparities between donors and recipients 
represent a powerful tool for the prediction of 
GvHD in unrelated HSCT. 
 Human leukocyte antigen G (HLA-G) and 
cytotoxic T lymphocyte associated antigen-4 
(CTLA-4) could play a role in immune 
modulation after HSCT  
 Killer immunoglobulin-like receptors (KIRs) 
have a prominent role in the development of 
GVHD 
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